ArticleVaccines2024
The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ
Abstract read
In one paragraph
Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial.Nature medicine · 2026Trial
- Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages.Emerging microbes & infections · 2025Trial
- Genetic diversity of the Chikungunya virus E2 gene may have implications for the design of vaccines and therapeutic antibodies.Virus genes · 2026Article
- The national burden from O'nyong'nyong and chikungunya viruses in Cameroon.medRxiv : the preprint server for health sciences · 2026Article
- Evaluation of Cross-Protective Responses against Mayaro Virus among Chikungunya Virus-Infected Patients from Paraguay.The American journal of tropical medicine and hygiene · 2026Article
- Review
- Chikungunya fever in Guangdong, China, 2025: rapid spread and challenges.Journal of thoracic disease · 2026Article
- Maturation-deficient chikungunya virus elicits protective immune responses in a murine challenge model.NPJ vaccines · 2026Article
- Investigating antibody cross-reactivity and transmission dynamics of alphaviruses and flaviviruses using a multiplex serological assay.Nature communications · 2026Article
- Viral emergence and pandemic preparedness in a One Health framework.Nature reviews. Microbiology · 2026Review
- Prohibitins: emerging host targets of bacteria and viruses at the plasma membrane, mitochondria, and cytoplasm.Microbial cell (Graz, Austria) · 2026Article
- Vector surveillance during a major chikungunya outbreak in northwestern São Paulo state, Brazil.Npj viruses · 2025Article
- A Review of the Biology of Chikungunya Virus Highlighting the Development of Current Novel Therapeutic and Prevention Approaches.Pathogens (Basel, Switzerland) · 2025Review
- A quantitative high-throughput screening pipeline to identify small molecule inhibitors of Chikungunya nsP2 protease.Scientific reports · 2025Article
- Chikungunya virus and other emerging arthritogenic alphaviruses.Nature reviews. Microbiology · 2025Review
- Potent Inhibition of Chikungunya Virus Entry by a Pyrazole-Benzene Derivative: A Computational Study Targeting the E1-E2 Glycoprotein Complex.International journal of molecular sciences · 2025Article
- Effectiveness of 3-amino-2-thiocyanato-α, β-unsaturated carbonyl compounds against chikungunya virus.Future medicinal chemistry · 2025Article
- Comprehensive Assessment of Reactogenicity and Safety of the Live-Attenuated Chikungunya Vaccine (IXCHIQVaccines · 2025Article
- Development of a virulent O'nyong'nyong challenge model to determine heterologous protection mediated by a hydrogen peroxide-inactivated chikungunya virus vaccine.PLoS neglected tropical diseases · 2025Article
- From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine.Journal of travel medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Whitney C WeberVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-5868-8085
Zachary J StreblowVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Craig N KreklywichVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Michael DentonVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Gauthami SulgeyVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0009-0006-1015-7281
Magdalene M StreblowVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Dorca MarcanoPonce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico.ORCID 0009-0004-6826-9580
Paola N FloresPonce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico.ORCID 0000-0003-2981-2320
Rachel M Rodriguez-SantiagoPonce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico.ORCID 0000-0001-6816-2610
Luisa I AlvaradoPonce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico.
Vanessa Rivera-AmillPonce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico.ORCID 0000-0003-4810-0871
William B MesserDepartment of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR 97239, USA.
Romana HochreiterValneva Austria GmbH, 1030 Vienna, Austria.
Karin KosulinValneva Austria GmbH, 1030 Vienna, Austria.ORCID 0000-0001-7397-9692
Katrin DubischarValneva Austria GmbH, 1030 Vienna, Austria.
Vera BuergerValneva Austria GmbH, 1030 Vienna, Austria.ORCID 0009-0008-9884-1006
Daniel N StreblowVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-6828-2492
Funding
Program in Biomedical SciencesT32GM142619 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Jeffrey Wallace Tyner · 2021 to 2026
$3.2MFlavivirus immunity in endemic and non-endemic human cohortsR01AI153434 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI MESSER, WILLIAM · 2021 to 2025
$2.3MG-RISE at Ponce Health Sciences UniversityT32GM144896 · NIGMS · PONCE SCHOOL OF MEDICINE · PI APPLEYARD, CAROLINE B · 2022 to 2024
$2.0MDengue virus immunity in endemic and non-endemic human cohortsR21AI135537 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI MESSER, WILLIAM · 2018 to 2019
$439kNIAID NIH HHS R01 AI153434NIAID NIH HHS R21 AI135537NIGMS NIH HHS T32 GM142619NIGMS NIH HHS T32 GM144896NIH HHS AI135537NIH HHS AI153434Valneva Sponsored research agreement (DNS)
Abstract
The first vaccine against chikungunya virus (CHIKV) was recently licensed in the U.S., Europe, and Canada (brand IXCHIQ
Indexed as
alphavirusesantibodybreadthchikungunya virus (CHIKV)cross-neutralizationinfectionIXCHIQvaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.